CJC-1295 (No DAC)
GHRH Analog Component
Other namesMod GRF 1-29, Modified GRF
TypeGHRH analog
Amino Acids29
Molecular Weight~3,367 g/mol
MechanismGHRH receptor agonist
Half-life (No DAC)30 min - 2 hours
⚠️ FOR RESEARCH PURPOSES ONLY — This compound is not FDA approved. All data presented is from clinical trials for educational reference.
Growth Hormone Secretagogue Peptide
CJC-1295 / Ipamorelin (No DAC)
4.9 (157 reviews)
Mod GRF 1-29 + IpamorelinModified GRF + IpamorelinCJC/Ipa Blend
A strategic peptide combination engineered to enhance gh release through synchronized GHRH and ghrelin receptor activation in experimental research models. Premium Research Peptide.
Dosage
Quantity
1
$59.99
Dosage
Quantity
1
$59.99
Thu, Apr 9 - Wed, Apr 15
Overnight shipping available
4 interest-free payments of $15.00We accept
CJC-1295 / Ipamorelin (No DAC)$59.99
Free shippingon orders over $150
60-day money-backguarantee
Secure checkout256-bit SSL
Certificate of Analysis
Third Party Tested by Freedom Diagnostics
Compound Information
Technical specifications
Teichman et al., 2006
Ipamorelin
Selective GHRP Component
TypeGrowth hormone secretagogue
Amino Acids5 (pentapeptide)
Molecular Weight711.85 g/mol
SequenceAib-His-D-2-Nal-D-Phe-Lys-NH2
MechanismGhrelin receptor (GHSR-1a) agonist
SelectivityNo cortisol/prolactin elevation
Blend Information
Why This Combination
Synergistic GH releaseDual-pathway activationPulsatile pattern preserved
Typical ratio1:1 by weight
Combined half-life1-2 hours (functional)
Synergy factor~2.7× vs single pathway
RouteSubcutaneous injection
Sources & References
Peer-reviewed research
Journal of Clinical Endocrinology & Metabolism
Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults
2006•DOI: 10.1210/jc.2005-1702•PMID: 16352683
Teichman SL, Neale A, Lawrence B et al.
View Source
European Journal of EndocrinologyIpamorelin, the first selective growth hormone secretagogue
1998•DOI: 10.1530/eje.0.1390552•PMID: 9849822
Raun K, Hansen BS, Johansen NL et al.
View Source
Journal of Clinical Endocrinology & MetabolismOn the actions of the growth hormone-releasing hexapeptide, GHRP
1991•PMID: 1919399
Bowers CY, Reynolds GA, Durham D et al.
View Source
Translational Andrology and UrologyA Review of Growth Hormone Secretagogues
2018•DOI: 10.21037/tau.2018.06.09•PMID: 30186644
Sigalos JT, Pastuszak AW
View Source
Journal of Clinical Endocrinology & MetabolismEffects of Growth Hormone and Its Secretagogues on Bone
1998•PMID: 9851737
Svensson J, Ohlsson C, Jansson JO et al.
View Source
Journal of Clinical Endocrinology & MetabolismOnce-Daily Administration of CJC-1295, a Long-Acting Growth Hormone-Releasing Hormone (GHRH) Analog, Normalizes Growth in the GHRH Knockout Mouse
2006•DOI: 10.1210/jc.2005-2371•PMID: 16670169
Alba M, Fintini D, Sagazio A et al.
View Source
⚠️Important Research Notice
Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.
